WebSep 17, 2024 · CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes Duchenne muscular dystrophy. CureDuchenne values companies like Dyne that utilize fundraising tools such … WebDyne Therapeutics (DYN) has a Smart Score of 7 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity. ... IPO Calendar Earnings Calendar. Popular. ... Dyne Therapeutics’s upcoming earnings report date is May 03, 2024 which is in 21 days. How were Dyne Therapeutics’s earnings ...
Dyne Therapeutics, Inc. (DYN) - Stock Analysis
WebSep 10, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday. The … WebMar 20, 2024 · In addition to DYNE-251, Dyne is building a global DMD franchise with preclinical programs for patients with mutations amenable to skipping other exons, including 53, 45 and 44. About Dyne ... chubb fire extinguisher video
DYN Stock Forecast, Price & News (Dyne Therapeutics)
WebMar 20, 2024 · Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases ... WebJan 18, 2024 · These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release. Contact: Dyne Therapeutics Amy Reilly areilly ... WebSep 16, 2024 · WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the pricing of its initial public offering of 12,251,578 chubb fire proof cabinets